Second Amendment to Bone Biologics Corporation 2015 Equity Incentive Plan
This amendment updates the Bone Biologics Corporation 2015 Equity Incentive Plan, effective May 30, 2025. It increases the total number of shares of common stock that may be issued under the plan to 30,629,489, including for incentive stock options. The amendment ensures that all stock awards and incentive stock options are subject to this new share limit and any future capitalization adjustments. The plan continues to govern how employees and others may receive equity-based compensation from the company.
Exhibit 10.1
SECOND AMENDMENT
TO THE
BONE BIOLOGICS CORPORATION
2015 EQUITY INCENTIVE PLAN
The Bone Biologics 2015 Equity Incentive Plan (the “Plan”) is hereby amended as follows, effective May 30, 2025:
3. Section 3(a)(i) of the Plan is hereby amended and restated in its entirety to provide as follows:
“(i) Subject to Section 9(a) relating to Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Stock Awards from and after the Effective Date will not exceed 30,629,489 (the “Share Reserve”).”
4. Section 3(c) of the Plan is hereby amended and restated in its entirety to provide as follows:
“(c) Incentive Stock Option Limit. Subject to the Share Reserve and Section 9(a) relating to Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options will be 30,629,489 shares of Common Stock.”
